In a recent study published in iScience, researchers have optimized the Tet-On system to improve the efficiency of generating skeletal muscle cells and other differentiated cell types from iPSCs for ...
OSLO, Norway--(BUSINESS WIRE)--Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation ...
Dose-escalation, first-in-human Phase I trial showed good safety and tolerability across all dose-cohorts, meeting the primary endpoint Data included observations of immune activation with vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results